Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

105.29USD
1:51am IST
Change (% chg)

$-0.71 (-0.67%)
Prev Close
$106.00
Open
$106.73
Day's High
$107.29
Day's Low
$104.94
Volume
1,408,304
Avg. Vol
2,400,471
52-wk High
$147.13
52-wk Low
$94.56

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $108,911.00
Shares Outstanding(Mil.): 782.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

Bluebird to seek approvals for three treatments by end of 2019

U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, chief executive Nick Leschly announced on Tuesday.

10 Jan 2018

CORRECTED-Bluebird to seek approvals for three treatments by end of 2019

Jan 9 U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, chief executive Nick Leschly announced on Tuesday.

10 Jan 2018

Celgene 2018 revenue forecast shy of estimates, shares fall

Celgene Corp , which has announced a deal to buy Impact Biomedicines, on Monday forecast 2018 total revenue that fell short of analysts' estimates, sending the U.S. biotech company's shares down 2 percent.

08 Jan 2018

BRIEF-Celgene CEO Says Plans To Invest Heavily In R&D In 2018

* CELGENE CEO SAYS PLANS TO INVEST HEAVILY IN RESEARCH AND DEVELOPMENT, BUSINESS DEVELOPMENT IN 2018

08 Jan 2018

BRIEF-Celgene Says Expects FY 2018 Rev To Be About $14.4 Bln To $14.8 Bln

* ORATION ANNOUNCES PRELIMINARY 2017 UNAUDITED RESULTS AND 2018 FINANCIAL GUIDANCE

08 Jan 2018

PRESS DIGEST -Wall Street Journal - Jan 8

Jan 8 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

08 Jan 2018

Celgene to buy Impact Biomedicines for up to $7 billion

NEW YORK U.S. biotech pharmaceutical firm Celgene Corp said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance.

08 Jan 2018

Celgene to buy Impact Biomedicines for up to $7 billion

NEW YORK U.S. biotech pharmaceutical firm Celgene Corp said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance.

08 Jan 2018

UPDATE 1-Celgene to buy Impact Biomedicines for up to $7 billion

NEW YORK, Jan 7 U.S. biotech pharmaceutical firm Celgene Corp said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance.

08 Jan 2018

Celgene readies deal to buy Impact Biomedicines for as much as $7 bln -WSJ

NEW YORK, Jan 7 Celgene Corp is expected to announce Monday that it is acquiring Impact Biomedicines for as much as $7 billion, the Wall Street Journal reported Sunday.

08 Jan 2018

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,446 +27.00
Eisai Co., Ltd (4523.T) ¥6,473 -58.00
Johnson & Johnson (JNJ.N) $146.98 +1.22
Novartis AG (NOVN.S) CHF83.56 +0.02
Pfizer Inc. (PFE.N) $36.62 +0.09
Roche Holding Ltd. (ROG.S) CHF236.00 -8.40
Roche Holding Ltd. (RO.S) CHF239.40 -8.20
Merck & Co., Inc. (MRK.N) $62.24 +3.58
Sanofi SA (SASY.PA) €73.40 +0.20
AstraZeneca plc (AZN.L) 5,049.00 -81.00

Earnings vs. Estimates